Primary Risk Drivers
Below is a snapshot of domains that materially influence the MARA Rating.
Clinical effectiveness
The clinical trial evidence indicates that pegunigalsidase alfa is statistically non-inferior to agalsidase beta, which is a standard treatment for Fabry disease. However, there is no direct comparison with agalsidase alfa or migalastat, and the evidence is primarily based on a single Phase 3 trial (BALANCE) with limitations in generalizability due to the specific patient population studied. Therefore, while the efficacy is comparable, the lack of direct evidence against all relevant comparators limits the strength of the claim.
Cost effectiveness
Economic evidence suggests that pegunigalsidase alfa is cost-saving compared to other enzyme replacement therapies (ERTs) and migalastat. The committee concluded that the cost-minimization analysis was appropriate given the assumption of clinical equivalence. The results indicate a favorable economic profile, supporting its recommendation.
Quality of life
The document indicates that the treatment has a positive impact on quality of life, but the evidence is not robust due to the low number of clinical events and the inability to derive comprehensive utility values from the BALANCE trial. The committee acknowledged that while there are expected benefits, the lack of strong utility data limits the confidence in the HRQoL improvements.
Supporting Domains
Safety and Adverse Effects
The safety profile of pegunigalsidase alfa appears acceptable, with a similar proportion of adverse events compared to agalsidase beta. The evidence suggests fewer infusion-related reactions, indicating a potentially better tolerability. However, the committee noted that the previous treatment with agalsidase beta might bias the results.
Comparator Selection
The treatment was compared against agalsidase beta in the BALANCE trial, which is appropriate. However, there is no direct evidence comparing pegunigalsidase alfa with agalsidase alfa or migalastat, which are also relevant treatments. The committee acknowledged that while the selected comparator is valid, the absence of direct comparisons with all relevant options limits the robustness of the evidence.
Patient Population and Subgroups
The trial population included adults with Fabry disease and impaired kidney function, which is representative of a significant portion of the patient population. However, the committee noted that the results may not generalize to all patients with Fabry disease, particularly those without kidney impairment or prior treatment.
Care Pathway Integration
Pegunigalsidase alfa can be integrated into existing treatment pathways for Fabry disease with minor adjustments. The treatment is an additional option for patients already receiving ERT, and the committee noted that it does not require significant changes to current clinical practice.
Resource Use and Cost Implications
The economic model indicates that pegunigalsidase alfa is cost-saving compared to existing treatments, which suggests a manageable budget impact. The committee recognized that while there are uncertainties, the overall resource implications are favorable.
Evidence Quality and Robustness
The evidence is primarily derived from a single Phase 3 trial, which has limitations in terms of generalizability and potential biases. While the trial design is robust, the lack of direct comparisons and the reliance on assumptions about clinical equivalence introduce uncertainties.
Uncertainty, Sensitivity, and Broader Impacts
The committee acknowledged some uncertainties regarding the economic model and the assumptions made about clinical equivalence. However, the context of unmet need and the potential benefits of the treatment provide a favorable backdrop for its recommendation.
